



US005674845A

**United States Patent** [19]  
**MacCuish**

[11] **Patent Number:** **5,674,845**  
[45] **Date of Patent:** **Oct. 7, 1997**

[54] **TREATMENT OF INSULIN-RESISTANT DIABETES**

[75] Inventor: **Angus Carstairs MacCuish**, Glasgow, Great Britain

[73] Assignee: **Fujisawa Pharmaceutical Co., Ltd.**, Osaka, Japan

[21] Appl. No.: **412,222**

[22] Filed: **Mar. 27, 1995**

**Related U.S. Application Data**

[63] Continuation of Ser. No. 829,004, filed as PCT/GB90/01399, Sep. 10, 1990, abandoned.

[30] **Foreign Application Priority Data**

Sep. 8, 1989 [GB] United Kingdom ..... 8920381

[51] **Int. Cl.**<sup>6</sup> ..... **A61K 37/36; A61K 37/26**

[52] **U.S. Cl.** ..... **514/12; 514/21**

[58] **Field of Search** ..... **514/12, 21**

**References Cited**

**FOREIGN PATENT DOCUMENTS**

0331630 9/1989 European Pat. Off. .  
0360411 3/1990 European Pat. Off. .

**OTHER PUBLICATIONS**

Diabetic, Journal of the British Association, Supplement of vol. 5, p. 7, 1988, J. D. Quin, et al., "A25. Mendenhall's Syndrome—A Therapeutic Dilemma".

The New England Journal of Medicine, vol. 317, No. 3, pp. 137-140, Jul. 16, 1987, Hans-Peter Guler, M.D., et al., "Short-Term Metabolic Effects of Recombinant Human Insulin-Like Growth Factor in Healthy Adults".

Diabetes/Metabolism Reviews, vol. 1, Nos. 1 & 2, pp. 189-191, 1985, S. I. Taylor, "Receptor Defects in Patients with Extreme Insulin Resistance".

The New England Journal of Medicine, vol. 317, No. 3, 16 Jul. 1987, H.P. Guler et al.: "Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults", pp. 137-140.

Diabetologia, vol. 31, 1988, Diabetologia Springer-Verlag, Pub., N. Livingston et al.: "Characterisation of insulin-like growth factor 1 receptor in skeletal muscles of normal and insulin resistant subjects", pp. 871-877.

*Primary Examiner*—Cecilia J. Tsang

*Assistant Examiner*—P. Lynn Touzeau

*Attorney, Agent, or Firm*—Oblon, Spivak, McClelland, Maier & Neustadt, P.C.

[57] **ABSTRACT**

Insulin-like growth factor (IGF) is used for treatment of type A insulin-resistant diabetes by reduction of glucose levels. The treatment is applicable to Mendenhall's Syndrome, Werner Syndrome, leprechaunism, lipoatrophic diabetes, and other lipoatrophies.

**11 Claims, 1 Drawing Sheet**